Patrick Machado - 21 May 2025 Form 4 Insider Report for ALUMIS INC. (ALMS)

Reporting relationship: Director
Issuer ticker: ALMS
Reported as of: 21 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 May 2025, 16:05:20 UTC
Prior SEC filing: 27 Jun 2024
Next SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Sara Klein, Attorney-in-Fact

Key filing fact

Patrick Machado filed Form 4 for ALUMIS INC. (ALMS) on 23 May 2025.

Key facts

This page summarizes Patrick Machado's Form 4 filing for ALUMIS INC. (ALMS).
6 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 23 May 2025, 16:05.

Change

Previous filing in this sequence was filed on 27 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001311210 Primary reporting owner

Machado Patrick

Relationship: Director
Address: C/O ALUMIS INC., 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Signature: /s/ Sara Klein, Attorney-in-Fact
Signature date: 23 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALMS transaction

Common Stock

Award

Transaction value
Shares: +7,064
Change %
Price
Shares after: 7,064
Date: 21 May 2025
Ownership: By Trust
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALMS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +44,364
Change %
Price
Shares after: 44,364
Date: 21 May 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 44,364
Exercise price: $9.26
Footnotes: F1, F3, F4, F5

ALMS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +11,189
Change %
Price
Shares after: 11,189
Date: 21 May 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 11,189
Exercise price: $37.39
Footnotes: F1, F4, F5, F6

ALMS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +41,499
Change %
Price
Shares after: 41,499
Date: 21 May 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 41,499
Exercise price: $12.21
Footnotes: F1, F4, F5, F7

ALMS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +13,804
Change %
Price
Shares after: 13,804
Date: 21 May 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 13,804
Exercise price: $12.21
Footnotes: F1, F4, F5, F8

ALMS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +19,528
Change %
Price
Shares after: 19,528
Date: 21 May 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 19,528
Exercise price: $1.60
Footnotes: F1, F4, F5, F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

On February 6, 2025, the Issuer entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with ACELYRIN, Inc., a Delaware corporation ("ACELYRIN"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into ACELYRIN (the "Merger"), with ACELYRIN surviving as a wholly owned subsidiary of Issuer. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of ACELYRIN issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Issuer, par value $0.0001 per share, and cash in lieu of any fractional shares.

Footnote F2

Shares held directly by Patrick Machado Revocable Trust, Patrick Machado, TEE, for which the Reporting Person serves as trustee.

Footnote F3

Received in the Merger in exchange for an employee stock option to acquire 92,158 shares of ACELYRIN common stock for $4.46 per share.

Footnote F4

Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Issuer and converted into an option to purchase a number of shares of Issuer Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding ACELYRIN stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.

Footnote F5

Stock Option is fully vested and exercisable.

Footnote F6

Received in the Merger in exchange for an employee stock option to acquire 23,243 shares of ACELYRIN common stock for $18.00 per share.

Footnote F7

Received in the Merger in exchange for an employee stock option to acquire 86,206 shares of ACELYRIN common stock for $5.8766 per share.

Footnote F8

Received in the Merger in exchange for an employee stock option to acquire 28,675 shares of ACELYRIN common stock for $5.8766 per share.

Footnote F9

Received in the Merger in exchange for an employee stock option to acquire 40,567 shares of ACELYRIN common stock for $0.7683 per share.